WSOPRAS and ITEDS Consensus Statement on the Assessment and Management of Thyroid Eye Disease

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Purpose: To develop a globally applicable consensus statement for the assessment and management of thyroid eye disease (TED). Methods: The World Society of Ophthalmic Plastic Reconstructive and Aesthetic Surgery council selected a 6-member, geographically diverse TED task force to develop a consensus statement on the assessment and management of TED. Consensus was achieved through monthly meetings from January to July 2025, alongside an analysis of the literature in terms of relevance, level of evidence, and global versus local applicability. A draft document was circulated to all World Society of Ophthalmic Plastic Reconstructive and Aesthetic Surgery constituent societies for feedback. Using a modified Delphi approach, the expert panel convened over 6 additional virtual sessions from July 2025 to March 2026 to review the submitted feedback, incorporating comments with agreement from at least 5 of 6 experts. The final statement was approved by both the World Society of Ophthalmic Plastic Reconstructive and Aesthetic Surgery council and the International Thyroid Eye Disease Society board of directors. Results: Consensus was achieved regarding methods, TED definitions, assessment, medical and surgical management, and safety recommendations. The consensus statement delineates acceptable standards, workup, and evaluation time points for basic-, intermediate-, and advanced-level assessment tailored to diverse global contexts, as well as tiered medical and surgical interventions, recommended for the different phases and severities of TED. Conclusions: The World Society of Ophthalmic Plastic Reconstructive and Aesthetic Surgery-International Thyroid Eye Disease Society consensus statement on TED, developed by oculoplastic and orbital surgeons, provides a global framework for the standardized assessment and management of TED to improve TED care and enhance patient outcomes.